Literature DB >> 11920231

Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.

J Meletis1, E Terpos, M Samarkos, C Meletis, E Apostolidou, V Komninaka, K Korovesis, D Mavrogianni, D Boutsis, E Variami, N Viniou, K Konstantopoulos, D Loukopoulos.   

Abstract

INTRODUCTION: Paroxysmal nocturnal hemoglobinuria is an acquired clonal stem cell disorder characterized by the decrease or absence of glycosylphosphatidylinositol-anchored molecules from the surface of the affected cells, such as CD55 and CD59, resulting in chronic intravascular hemolysis, cytopenia and increased tendency to thrombosis. PNH-phenotype has been described in various hematological disorders, mainly in aplastic anemia and myelodysplastic syndromes, while it has been reported that complete deficiency of CD55 and CD59 has also been found in patients with lymphoproliferative syndromes, like non-Hodgkin's lymphomas.
MATERIALS AND METHODS: The presence of CD55- and/or CD59-defective red cell populations was evaluated in 217 patients with lymphoproliferative syndromes. The study population included 87 patients with NHL, 55 with HD, 49 with CLL, 22 with ALL and four with hairy cell leukemia. One hundred and twenty-one healthy blood donors and seven patients with PNH were also studied as control groups. The sephacryl gel microtyping system was performed for the detection of CD55- and CD59-deficient red cell populations. Ham and sucrose lysis tests were also performed in all samples with CD55 or CD59 negative populations.
RESULTS: Red cell populations deficient in both CD55 and CD59 molecules were detected in 9.2% of patients with lymphoproliferative syndromes (more often in ALL and nodular sclerosis type of HD) and in all PNH patients. CD55-deficient red cell populations were found in 8.7% of LPS patients (especially in low grade B-cell NHL), while CD59-deficient populations were found in only two patients with low grade B-cell NHL.
CONCLUSION: These data indicate a possible association between paroxysmal nocturnal hemoglobinuria phenotype and lymphoproliferative syndromes, while further investigation is necessary to work out the mechanisms and the significance of the existence of this phenotype in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11920231     DOI: 10.1038/sj.thj.6200077

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  7 in total

1.  Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias.

Authors:  John Meletis; Evangelos Terpos; Michalis Samarkos; Christos Meletis; Effie Apostolidou; Veroniki Komninaka; Konstantinos Korovesis; Konstantinos Anargyrou; Olga Benopoulou; Despina Mavrogianni; Eleni Variami; Nora Viniou; Konstantinos Konstantopoulos
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

2.  Characterization and statistical modeling of glycosylation changes in sickle cell disease.

Authors:  Heather E Ashwood; Christopher Ashwood; Anna P Schmidt; Rebekah L Gundry; Karin M Hoffmeister; Waseem Q Anani
Journal:  Blood Adv       Date:  2021-03-09

3.  Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.

Authors:  Evangelos Terpos; Michalis Samarkos; Christos Meletis; Effie Apostolidou; Maria Tsironi; Konstantinos Korovesis; Despina Mavrogianni; Nora Viniou; John Meletis
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: successful intervention with eculizumab and fondaparinux.

Authors:  Kit L Cheng; Judith Brody; Craig E Warshall; Elaine M Sloand; Steven L Allen
Journal:  Leuk Res       Date:  2010-04       Impact factor: 3.156

5.  The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.

Authors:  John V Asimakopoulos; Evangelos Terpos; Loula Papageorgiou; Olga Kampouropoulou; Dimitris Christoulas; Anastasios Giakoumis; Michael Samarkos; George Vaiopoulos; Konstantinos Konstantopoulos; Maria K Angelopoulou; Theodoros P Vassilakopoulos; John Meletis
Journal:  Med Sci Monit       Date:  2014-01-27

Review 6.  The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.

Authors:  Christopher B Toomey; David M Cauvi; Kenneth M Pollard
Journal:  Autoimmune Dis       Date:  2014-01-27

7.  JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature.

Authors:  Sevastianos Chatzidavid; Nefeli Giannakopoulou; Panagiotis Theodorou Diamantopoulos; Eleni Gavriilaki; Panagiota Katsiampoura; Eleftheria Lakiotaki; Stratigoula Sakellariou; Nora-Athina Viniou; Georgios Dryllis
Journal:  Thromb J       Date:  2021-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.